Assay methods and compositions for detecting nucleic acid identifier contamination

By attaching a constant region to a nucleic acid sample and amplifying it with specific primers, combining mixing pools and sequencing methods, the high cost and inefficiency of nucleic acid sample contamination detection in the prior art is solved, and efficient and accurate sample identifier sets are achieved identification and identification of pollution sources.

CN110892079BActive Publication Date: 2024-11-08AGILENT TECHNOLOGIES INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN201880045248.6
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2017-07-10
Filing Date
2018-05-10
Publication Date
2024-11-08
Estimated Expiration
2039-03-13

AI Technical Summary

Technical Problem

Prior art When detecting contaminated sample barcodes in nucleic acid samples, the method is expensive, inefficient and prone to false positives, and it is difficult to effectively separate and identify contamination sources in multiple samples.

Method used

Amplification is performed using assay primers and second primers to ensure uniqueness of sample identifiers in each container and through mixing and sequencing by attaching 5' constant regions and Methods identify contamination sources, reduce the number of treatment steps and sequencing runs.

Benefits of technology

The uniqueness of the sample identifier group in the absence of pollution is achieved, the cost and time of pollution detection is reduced, the reliability of sequence information is improved, and the misinterpretation of contamination between samples is reduced.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN110892079B_ABST
    Figure CN110892079B_ABST
Patent Text Reader

Abstract

The present invention relates to nucleic acid samples for massively parallel sequencing. More specifically, the present invention relates to assays, compositions and kits for detecting contamination of nucleic acid identifiers such as sample barcodes.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims the benefit of U.S. Nonprovisional Application No. 15 / 645,085, filed on July 10, 2017, which is hereby incorporated by reference in its entirety. Field of the Invention

[0003] The present invention relates to the field of molecular biology. In particular, the present invention relates to assay methods and compositions for detecting contamination of nucleic acid identifiers such as sample barcodes. Background of the Invention

[0005] Identifiers (such as sample barcodes or molecular barcodes) can be present in nucleic acids for a variety of purposes. Most commonly, sample barcodes are added to nucleic acid molecules of interest before such nucleic acid molecules are amplified and / or sequenced, so that the origin or source of sequence information can be identified. Nucleic acid molecules from different samples can be merged together and sequenced in parallel on a large scale to effectively determine sequence information from many different samples. Before sequencing, sample identifiers (commonly referred to as sample barcodes) can be added to nucleic acid molecules, which contributes to grouping, analysis and interpretation of information. As another example, molecular barcodes can be added to target nucleic acid molecules before amplification, so that the repetitions of the initial target molecules can be identified and grouped together subsequently.

[0006] Sample barcodes are often used with target molecules to be analyzed by massively parallel sequencing so that nucleic acid molecules from different samples can be pooled for sequencing and sequence information can be assigned to the samples. In some cases, scientists and laboratories performing massively parallel sequencing will detect sample barcodes in the pool even if the sample barcodes are not included in the sequencing pool. This indicates the presence of contaminating sample barcodes in the pooled nucleic acids, which may be caused by the inclusion of more than one sample barcode sequence (i.e., the desired barcode sequence and the contaminating barcode sequence) in the sample barcode aliquot. Contaminating barcodes may be introduced at any stage of sample barcode aliquot preparation, starting from the earliest stages, including the synthesis and purification of DNA oligonucleotides, or through processing steps during the dilution and aliquoting of sample barcode sequences. Even when present at a low frequency (such as 1% or less), the presence of contaminating sample barcodes can cause problems with the reliability and interpretation of sequence information.

[0007] Sample barcodes are typically provided in a set of containers (such as a well plate), where each container holds a different sample barcode. When sample barcodes are used for laboratory analysis, such as by pipetting the sample barcodes from their containers into various samples to be analyzed, there is a risk that the containers or samples may become contaminated.

[0008] By preparing separate sequencing libraries for each sample barcode and sequencing them separately, the contamination of the sample barcode can be detected. Alternatively, such a mixed pool scheme can be used to detect contamination, by which the contamination of the sample barcode in at least one pool and another sample barcode can be compared. However, in order to separate the barcodes from a large number of samples (such as 48 or 96 samples), a large number of pools must be prepared and sequenced in their respective sequencing runs. This will be expensive, inefficient and time-consuming. This method is also likely to mistakenly find contamination in the sample barcode that is not present in the test tube, but introduced in one of the many library preparation steps, resulting in false positives. SUMMARY OF THE INVENTION

[0010] As one aspect of the present invention, there is provided a method for attaching a determination identifier (e.g., a quality control barcode) to a group of oligonucleotide samples comprising oligonucleotides, wherein each oligonucleotide comprises a 5' constant region, a sample identifier (e.g., a sample barcode) and a 3' constant region, and each sample identifier is unique in the group in the absence of contamination. In some embodiments, the constant region comprises a standard amplification region or its reverse complementary sequence for a sequencing platform. For example, in some embodiments, the 5' constant region is an Illumina Index 1 sequence, and the 3' constant region is the reverse complementary sequence of the Illumina P7 sequence (P7'), and in other embodiments, the direction is opposite, so that the 5' constant region is an Illumina P7 sequence, and the 3' constant region is an Illumina Read 2 sequence. The method includes providing each oligonucleotide sample of the group in a separate container so that each container only comprises a sample identifier, unless one or more samples are contaminated. The method also includes amplifying oligonucleotides in each container with a determination primer and a second primer. The assay primers comprise one or more constant regions (such as P5 and Read 1 primer sequences), an assay identifier, and a priming portion that is identical or complementary to one of the constant regions of the oligonucleotide. Unless one or more assay primers are contaminated, each container comprises only one assay identifier. Thus, the method provides an oligonucleotide amplicon comprising an assay identifier and a sample identifier.

[0011] As another aspect, a method for detecting contamination in a group of oligonucleotides comprising a sample identifier is provided. The method includes providing a group of oligonucleotide samples comprising oligonucleotides, wherein each oligonucleotide has a 5' constant region, a sample identifier (such as a sample barcode) and a 3' constant region. Each oligonucleotide in a sample has the same sample identifier, and each sample in the group has a different sample identifier unless one or more samples are contaminated. The method also includes amplifying the oligonucleotide or the complementary sequence of the oligonucleotide with a determination primer and a second primer. Different determination primers are used for each sample, and each determination primer includes a priming portion and a determination identifier (such as a QC barcode), thereby generating a group of oligonucleotide amplicons. Each oligonucleotide amplicon includes one of the determination identifiers, a 5' constant region, one of the sample identifiers and a 3' constant region. The method also includes merging the oligonucleotide amplicons in one or more pools; sequencing one or more pools to determine the sequence information of at least the sample identifier and the determination identifier of the oligonucleotide amplicons; determining whether the sample identifier in the first pool includes a contaminating sample identifier; and determining whether the determination identifier in the first pool includes a contaminating determination identifier.

[0012] In some embodiments, the method of the present invention includes mixing the oligonucleotide amplicons into at least two pools, and sequencing the first pool and the second pool respectively to determine the sequence of at least the sample identifier and the assay identifier of the oligonucleotide amplicons. The method of the present invention may also include determining whether the sample identifier in the second pool includes a contaminating sample identifier. In some embodiments, the method of the present invention also includes determining whether the assay identifier in the second pool includes a contaminating assay identifier. In some embodiments, the method of the present invention further includes identifying the contaminating sample identifier in the first pool by determining that the contaminating sample identifier is from the second pool. In some embodiments, the method of the present invention further includes identifying the contaminating sample identifier in the first pool by determining that the second pool does not include the contaminating assay identifier. In some embodiments, the method of the present invention further includes identifying the contaminating assay identifier in the first pool by determining that the second pool includes the contaminating assay identifier. In some embodiments, the contaminating sample identifier is determined by one or both of the following: (i) identifying one or more sample identifiers associated with more than one assay identifier, and (ii) identifying the assay identifier associated with more than one sample identifier.

[0013] As another aspect, a composition for an assay suitable for determining contamination in a set of oligonucleotides comprising a sample identifier is provided. The composition comprises at least one oligonucleotide having a 5' constant region, a sample identifier (such as a sample barcode) and a 3' constant region, and at least one assay primer comprising a priming portion and an assay identifier. In some embodiments, the composition further comprises one or more of a DNA polymerase and a deoxynucleotide.

[0014] As another aspect, a test kit for determining a group of contamination in an oligonucleotide comprising a sample identifier is provided. The test kit comprises at least 8 assay primers, or at least 16 assay primers, or at least 32 assay primers, or at least 48 primers or at least 96 primers in a separate container. Every assay primer identifier comprises a priming portion and an assay identifier.

[0015] In some embodiments of the aforementioned aspects, the group or pool of oligonucleotide samples comprises at least 8 samples, or at least 16 samples, or at least 32 samples, or at least 48 samples, or at least 96 samples, wherein each sample has a sample identifier unique in the group or pool. In some embodiments, a set of assay primers comprises at least 32 assay identifiers, or at least 48 assay identifiers, or at least 96 assay identifiers, wherein each assay primer has an assay sample identifier unique in the group or pool. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] Figure 1A , 1B and 1C show an embodiment of a method of the present invention for attaching an assay identifier to an oligonucleotide having a sample identifier.

[0018] Figure 2 The sequences of two different embodiments of assay primers according to the present disclosure are shown. Both embodiments contain many identical regions, but the 5' constant region is different. In version 2, there is less overlap between the 5' constant region and the 3' constant region.

[0019] Figure 3 Shows the use Figure 2 The assay primers of the first embodiment provide a size distribution of amplicons amplified from an oligonucleotide.

[0020] Figure 4 Shows the use Figure 2 The second embodiment of the assay primers provides a size distribution of amplicons amplified from an oligonucleotide.

[0021] Figure 5Another embodiment of the method of the invention for attaching an assay identifier to an oligonucleotide having a sample identifier is shown, wherein the identifier is attached at the 3' position relative to the sample identifier.

[0022] Figure 6 Another embodiment of the method of the invention for attaching an assay identifier to an oligonucleotide having a sample identifier, wherein the constant region of the oligonucleotide is incompatible with the desired sequencing platform is shown.

[0023] Figure 7 A pooling scheme is shown for detecting contamination of sample identifiers using the methods and compositions of the present invention. DETAILED DESCRIPTION OF THE INVENTION

[0025] The methods, compositions and kits of the present invention can be used to detect contamination in a set of oligonucleotides of a nucleic acid sample and allow the generation of a substantially contamination-free set of sample identifiers. This is a significant advancement and benefit, as the presence of sample barcode contamination can lead to misinterpretations of genetic variants, with serious consequences for research and clinical applications.

[0026] Described method, composition and test kit adopt the oligonucleotide with 5 ' constant region, sample identifier and 3 ' constant region.Each oligonucleotide in a sample has the same sample identifier, and every kind of sample in described group has different sample identifiers, unless one or more samples are subjected to the pollution of contaminating sample identifier.In some embodiments, each sample in described group has the sample identifier that is unique in this group, which means that it is expected and will be unique when there is no pollution.

[0027] "Sample identifier" includes a sample barcode or any degenerate or random sequence that can be used to identify a sample. The sample identifier can be flanked (directly or indirectly) by a constant region. In some embodiments, the sample identifier can be a sample barcode comprising 6 or more random or degenerate nucleotides; or, the sample identifier can be a sample barcode comprising 8 or more random or degenerate nucleotides or 10 or more random or degenerate nucleotides. In some embodiments, the sample identifier comprises 8 known bases, and the assay identifier comprises 10 degenerate bases. In other embodiments, the sample identifier comprises 4 known bases or 6 known bases. In some embodiments, the number of bases in the sample identifier can be selected based on the number of samples to be distinguished. Longer sample identifiers and sample barcodes are also possible. For example, a sample identifier comprising 18 bases (8 known bases and 10 degenerate bases) has been used to prepare an oligonucleotide library for the Ion Torrent sequencing platform. Sample identifiers with more than 19 bases are also feasible and may be desirable, especially if the assay is used for other sequencing platforms and applications. In some embodiments, the complement of the original sample barcode is present in the oligonucleotide amplicon, which is also considered a sample identifier.

[0028] "Constant" region is a region comprising known sequences, and, because it is known, it can play a desired function. Constant region will generally be identical or substantially identical in a group of oligonucleotides. Known sequences can be used as the initiation site (region) of amplification or primer extension, and / or can be hybridized with nucleic acids attached to a support. In some embodiments, constant region includes the sequence of a standard region (such as the standard amplification region used in a sequencing platform). Constant region can include a certain number of nucleotides from a known region or a standard region, which is sufficient for the function of the standard region, such as a sufficient number of nucleotides hybridized with the standard primers for amplification.

[0029] A "contaminating" molecule or sequence is one that is not designed to be present in a group or pool, or should not be present in a group or pool or sample unless some contamination is present. For example, if a barcode in a first group or pool sequence should not be present in the first group or pool, and / or should only be present in a second group or pool, then the barcode is a contaminating barcode.

[0030] Method and composition of the present invention provide the solution to the problem of identification of contamination in the oligonucleotide group comprising sample identifier (such as sample barcode).Present technology has relatively few processing steps, which is desirable because the processing steps increase the risk of contamination.In addition, a kind of mixed pool scheme and analytical method are provided, which can reduce the number of pools and sequencing runs required for detecting contamination between samples.Present method can reduce the number of pools for detecting contamination in a group of 96 sample identifiers, without a lot of pools.In some embodiments, two sequencing pools are used to detect the sample identifier pollution in a group of 96 sample identifiers.

[0031] The methods and compositions of the invention can also be used to amplify oligonucleotides (such as library molecules, adapters, aptamers or other ssDNA molecules for targeting proteins or peptides) with a series of random nucleotides (considered herein as sample identifiers) between two constant regions to detect sequence diversity, including detection of molecular barcodes. It can also be used to identify single nucleotide polymorphisms (SNPs) or mutagenic sites in known regions of DNA.

[0032] The oligonucleotides that can be measured by the method of the present invention include adapters of nucleic acid molecules or regions from standard adapters, such as amplification regions from standard adapters for sequencing platforms. Oligonucleotides can also include markers, tags or other modules. For example, oligonucleotides include biotin modules that allow oligonucleotides to be enriched by binding to avidin or streptavidin. This method is used for commercially available Haloplex kits (Agilent Technologies). Oligonucleotides that can be measured by the method of the present invention include library molecules, which are molecules prepared as a part of the library of a sequencing platform. Library molecules generally include inserts, and sample identifiers and one or more standard regions for sequencing platforms are attached to the inserts. Other regions can also be included in library molecules. For library molecules, sample identifiers can be molecular barcodes, or can be second sample barcodes in addition to the first sample barcode.

[0033] The method also includes measuring primers and the second primer amplification oligonucleotide or the complementary sequence of the oligonucleotide. Different measuring primers are used for every sample, and each measuring primer comprises a triggering portion and a measuring identifier (such as a QC barcode), thereby generating a group of oligonucleotide amplicon. Each oligonucleotide amplicon comprises one of the measuring identifier, a 5' constant region, one of the sample identifier and a 3' constant region. By selecting the corresponding standard constant region with various standardized sequencing platforms (for example, Illumina and IonTorrent sequencing platforms), this assay method can be easily applicable to these platforms.

[0034] In some embodiments, the method detects sample identifier contamination at a level of less than 1%, or less than 0.5%, or less than 0.1%, wherein a small number of processing steps are used to avoid or prevent contamination caused by the assay; and a pooling and analysis method is provided so that the number of sequencing runs is small. The present disclosure provides a rapid and relatively inexpensive method for preparing libraries from oligonucleotides with potential contamination of sample identifiers. These libraries are suitable for sequencing on one or more desired sequencing platforms, especially massively parallel sequencing.

[0035] In some embodiments, the oligonucleotide amplicon comprises a 5' constant region and a 3' constant region. In addition, the 5' constant region comprises a standard 5' adapter for a sequencing platform and a sequencing priming region, a determination identifier, an intermediate constant region comprising a sequencing priming region, a sample identifier, and a 3' constant region comprising a standard 3' adapter for a sequencing platform. In some embodiments, the oligonucleotide amplicon comprises (i) a 5' constant region comprising a standard 5' adapter for a sequencing platform and a sequencing priming region, (ii) a determination identifier, (iii) an intermediate constant region comprising a sequencing priming region, (iv) a sample identifier, and (v) a 3' constant region comprising a standard 3' adapter for a sequencing platform. For example, a standard 5' adapter may comprise an Illumina P5 or P5' sequence, and a standard 3' adapter may comprise an Illumina P7 or P7' sequence. P7' represents the complementary sequence of P7; similarly, P5' represents the complementary sequence of P5. In other embodiments, the oligonucleotide amplicon comprises a 5' constant region comprising a standard 5' adapter, a sample identifier, an intermediate constant region, a determination identifier, and a 3' constant region comprising a standard 3' adapter.

[0036] The methods, compositions and kits of the present invention can also be used to modify an oligonucleotide comprising a standard region (e.g., an amplification region or a sequencing primer site (region)) of a first sequencing platform so that it comprises a standard region of another different sequencing platform. In some embodiments, the second primer comprises a 3' region complementary to the 3' constant region of the oligonucleotide, and the second primer further comprises a 5' region containing a standard amplification region, wherein the 3' constant region of the oligonucleotide comprises a standard amplification region of a sequencing platform different from the standard amplification region of the 5' region of the second primer.

[0037] The present disclosure also provides novel pooling and sequencing schemes for identifying contamination of sample identifiers and assay identifiers. In some embodiments, the method of the present invention includes: pooling oligonucleotide amplicons into at least two pools; sequencing the two pools to determine at least a partial sequence of the oligonucleotide amplicons, which at least a partial sequence includes a sample identifier and an assay identifier; determining whether the sample identifier in the second pool includes a contaminating sample identifier; determining whether the assay identifier in the second pool includes a contaminating assay identifier. In some embodiments, the method of the present invention further includes determining the contaminating sample identifier by determining that the contaminating sample identifier is from the second pool. In some embodiments, the method further includes identifying the contaminating sample identifier by determining that the second pool does not include the contaminating assay identifier. In some embodiments, the method of the present invention further includes identifying the contaminating assay identifier by determining that the second pool does not include the contaminating assay identifier.

[0038] In some embodiments, the method of the present invention further comprises grouping the sequences of the oligonucleotide amplicons according to the assay identifier to form assay groups; and determining whether there is more than one sample identifier sequence in each assay group. In some embodiments, the method of the present invention further comprises grouping the sequences of the oligonucleotide amplicons according to the sample identifier to form sample groups; and determining whether there is more than one assay identifier sequence in each sample group. In some embodiments, the method comprises forming at least two pools from the oligonucleotide amplicons; and sequencing the at least two pools of amplicons to obtain sequence information of the oligonucleotide amplicons; wherein the sequence information of each oligonucleotide amplicon comprises at least the sequence of the assay identifier and the sample identifier. In some embodiments, the method of the present invention may comprise grouping the amplicon sequence information according to the assay identifier; and determining whether the grouped amplicon sequence information comprises more than one sample identifier.

[0039] The method may include determining whether there is a mismatch between the assay identifier and the sample identifier, for example, a mismatch in which at least one sample identifier is associated with an assay identifier that should not be associated therewith, and / or a mismatch in which at least one assay identifier is associated with a sample identifier that should not be associated therewith.

[0040] The methods of the present invention can be used with sample preparation kits for NGS. They can also be used with library preparation reagents. The methods of the present invention can also be used to assay target enrichment kits and kits containing sample barcodes or other identifiers, including SureSelect kits. The SureSelect kit (available from Agilent Technologies) contains oligonucleotides, i.e., PCR primers, having a sample identifier and having one or more constant regions at 5' and 3' of the sample identifier.

[0041] The present disclosure allows for the production of sample identifier sets or kits that are substantially free of contamination, such as having less than 0.1% or less than 0.01% contaminating sample identifiers.

[0042] exist Figure 1A In the method, oligonucleotide 102 comprises a 5' constant region 110, a sample identifier 112 and a 3' constant region 114. For example, the 5' constant region 110 may comprise a standard sequence such as an Illumina Index 1 sequence, a sample identifier 112, and the 3' constant region 114 may comprise a standard amplification sequence, such as an Illumina P7' sequence. The constant region may comprise any standard priming site (region) for amplification or sequencing. The oligonucleotide 102 is amplified using a primer 104 having a priming region 115 complementary to at least a portion of the 3' constant region 114. For example, the primer 104 may be a P7 primer. In the same step or a subsequent step, the oligonucleotide 102 or its complement is amplified using a primer 106 having a priming region 120 complementary to at least a portion of the 5' constant region 110 or its complement 111. The primer also comprises an assay identifier 122 and one or more constant regions 126, 124 (e.g., an Illumina P5 sequence 126 and a Read 1 sequencing primer 124). Several additional rounds of amplification produce oligonucleotide amplicons 108, which include one or more constant regions 126, 124, assay identifier 122, the sequence of the 5' constant region 120 of the initial oligonucleotide, a sample identifier sequence 128, and the 3' constant region 130 of the initial oligonucleotide. The sample identifier sequence 128 in the amplicon 108 is typically an identical copy of the sample identifier 112 of the oligonucleotide 102. The constant region 120 of the amplicon 108 will be almost identical to the constant region 110 of the oligonucleotide 102, but either will be partially truncated. For example, the constant region 110 may be truncated at the 5' end, and the constant region 120 may be truncated at the 3' end. Similarly, the constant region 130 of the amplicon 108 and the constant region 114 of the oligonucleotide 102 are typically identical, although the constant region 114 may be partially truncated at the 3' end, and the constant region 130 may be partially truncated at the 5' end. Due to the constant region, the oligonucleotide amplicons 108 are suitable for sequencing on a standard platform for large-scale parallel sequencing.

[0043] Figure 1BAnother embodiment of the method of the present invention is shown. In this embodiment, oligonucleotide 103 comprises 3' constant region 111, sample identifier 113 and 5' constant region 115. For example, 3' constant region 111 can be Illumina Read 2 sequence (or another standard region of sequencing platform), and 5' constant region 115 can be Illumina P7 sequence or any standard priming site (region) for amplification or sequencing. Amplification produces oligonucleotide amplicon 109, which comprises one or more constant regions 127, 125, assay identifier 123, 3' constant region 111, sample identifier sequence 113 and 5' constant region 115 sequence. Additional rounds of amplification can be performed with primer 131, which has a sequence that is sufficient to be used as a primer and is identical to a portion of constant region 115.

[0044] Figure 1CShown how the assay method can be carried out when the initial oligonucleotide is a library molecule, the library molecule is a molecule comprising an insert, wherein the sample identifier and the standard area for sequencing platform are attached to the insert. In this embodiment, the assay method can detect the pollution occurring during library preparation. Oligonucleotide 102 comprises a first 5' constant region 110, a sample identifier 112, a 3' constant region 114, and further comprises an insert 140, a second 5' constant region 142 (such as Read 1 initiation site), an optional second sample identifier 144 and the 3rd 5' constant region 146 (for example, amplification initiation site). Insertion 140 comprises a target sequence to be studied, analyzed or subjected to other tests (such as sequencing on a large-scale parallel sequencing platform). The second sample identifier 144 is optionally included in many library preparations. Oligonucleotide 103 (which is the complementary strand of oligonucleotide 102) comprises a first 3' constant region 111, a sample identifier 113, a 5' constant region 115, and further comprises an insert 141, a second 3' constant region 143 (such as a Read 1 priming site), an optional second sample identifier 145, and a third 3' constant region 147 (e.g., an amplification priming site). Oligonucleotide 102 is amplified using an assay primer 104 having a priming region 115 complementary to at least a portion of the 3' constant region 111. For example, primer 104 can be a P7 primer. In the same step or a subsequent step, oligonucleotide 102 or its complement is amplified using a primer 106 having a priming region 120 complementary to at least a portion of the 5' constant region 110 or its complement 111. The primer also comprises an assay identifier 122 and one or more constant regions 126, 124 (e.g., an Illumina P5 sequence 126 and a Read 1 sequencing primer region 124). Additional rounds of amplification produce oligonucleotide amplicons 108, which include one or more constant regions 126, 124, an assay identifier 122, the sequence of the 5' constant region 120 of the initial oligonucleotide, a sample identifier sequence 128, and the 3' constant region 130 of the initial oligonucleotide. In the embodiment shown, the oligonucleotide amplicon 108 does not include the insert 140, but in some embodiments, the primer 106 binds the region 3' to the insert 140 and thereby includes the insert 140 in the amplicon. The pooling method (as described in Example 4) can be applied to libraries prepared with two or more sample barcodes (where the barcodes are attached by ligation or amplification), and the pooling method can be used to identify whether sample barcode contamination occurs after library preparation is performed.

[0045] By selecting the constant region and the priming region on the assay primers, this method can be adapted to different library preparation methods (including Haloplex XTHS, Haloplex HS, SureSelect XT and SureSelect QXT, all from Agilent) and different standardized sequencing platforms (including Illumina and Ion Torrent). Sequencing platforms for massively parallel sequencing include the Ion Torrent PGM and Proton semiconductor sequencers, as well as the Illumina MiSeq, HiSeq, MiniSeq and NextSeq. Other sequencing platforms are under development, and the compositions and methods of the invention can be used with the standard amplification regions of those platforms.

[0046] In some embodiments, the constant region on the oligonucleotide and / or assay identifier comprises a sequence suitable for use on a standardized sequencing platform. For example, the constant region may have a sequence for an amplification region of an Illumina sequencing platform, such as an Illumina P5 sequence or an Illumina P7 sequence, or such as an Ion Torrent Adapter A sequence or an IonTorrent Adapter P1 sequence, or such as a sequencing primer region, such as an Illumina Read1, Index1, Read2, or Index2. Other amplification regions or sequencing primer regions may be used for different platforms. Table 1 lists the sequences of the standard regions currently used in Illumina and IonTorrent sequencing platforms:

[0047] Table 1

[0048]

[0049]

[0050] In some embodiments, the oligonucleotide constant region comprises a sequence selected from the sequences listed in Table 1.

[0051] Figure 5 It is shown how the methods and compositions of the invention can be used to add an assay identifier at the 3' position relative to the sample identifier. This method is particularly suitable for oligonucleotides that are configured for attachment to an adaptor at the 5' end of a target molecule to be sequenced, or a primer for amplifying the 5' end of a target molecule. Thus, in this embodiment, the method of the invention is particularly suitable for detecting an identifier present in a 5' adaptor (and is an alternative to a 3' adaptor as shown in Figure 1).

[0052] exist Figure 5In the embodiment of the present invention, oligonucleotide 502 comprises a 5' constant region 510, a sample identifier 512, and a 3' constant region 514. For example, the 5' constant region 510 can be an Illumina P5 sequence, the sample identifier 512 can be a sample barcode, and the 3' constant region 514 can be an Illumina Read 1 sequence. Oligonucleotide 502 is amplified using a primer 504 having a priming region 515 complementary to at least a portion of the 3' constant region 514. For example, the priming region 515 can be the reverse complement of the 3' constant region 514, i.e., the reverse complement of the Illumina Read 1 sequence. Primer 504 also comprises an assay identifier 517 and an adapter 519 for a sequencing platform or its complement, such as the reverse complement of Illumina P7 (P7'). Oligonucleotide 502 or its complement is amplified using a primer 506 having a priming region 520 complementary to at least a portion of the 5' constant region 510 or its complement. Additional rounds of amplification produce oligonucleotide amplicons 508, which include a 3' adaptor 518, assay identifiers 522, 516, a 3' constant region 514, a sample identifier 512, and a 5' constant region 520. Oligonucleotide amplicons 508 are suitable for sequencing on a standard platform for massively parallel sequencing because at least one (and often both) constant regions include an adaptor for use on such platforms.

[0053] Figure 6 It is shown how the assay methods and compositions of the present invention can be used to detect contamination in oligonucleotides when the oligonucleotide is surrounded by two constant regions and neither of these constant regions is compatible with the sequence platform to be used for the assay. Alternatively, this method can be used to convert adapters and primers from one sequencing platform so that they can be sequenced on another platform. For example, oligonucleotides such as adapters used in the Ion Torrent HaloPlex assay can be assayed using assay primers and amplification primers, the assay primers comprising: Illumina P5, QXT Read1, QC index, IonTorrent Read primers; and the amplification primers comprising: Illumina P7 and the reverse complement of the Haloplex dark base (dark bases are those bases that do not produce fluorescence associated with nucleotide incorporation during sequencing). This allows the contamination of these primers to be determined on the Illumina sequencer. This method can also be used for sequencing of oligonucleotides that are not intended for sequencing and do not include amplification regions for sequencing platforms, provided that those oligonucleotides contain 5' constant regions, unknown regions, and 3' constant regions.

[0054] exist Figure 6In the embodiment, oligonucleotide 602 comprises a 5' constant region 610, a sample identifier 612, and a 3' constant region 614. In this embodiment, the constant regions 610, 614 of oligonucleotide 602 are used for a first sequencing platform, such as an Ion Torrent sequencing platform, but it is desired to sequence oligonucleotide 602 on a second sequencing platform, such as an Illumina sequencing platform. For example, 5' constant region 610 can be an Ion Torrent Adapter A sequence, sample identifier 612 can be a sample barcode, and 3' constant region 614 can be a dark base provided for ligation and quality control. Oligonucleotide 602 is amplified using a primer 604 having a priming region 615 that is complementary to at least a portion of the 3' constant region 614 (i.e., complementary to at least a portion of the dark base). Primer 604 also includes a region 617 that includes a region corresponding to a standard amplification region of a sequencing platform, such as an Illumina P7 sequence. Oligonucleotide 602 or its complementary sequence is amplified with primer 606 having a priming region 620 complementary to at least a portion of 5' constant region 610 or its complementary sequence 611. The primer 606 also comprises an assay identifier 622 and one or more constant regions (e.g., Illumina P5 sequence 626 and Illumina Read 1 sequence 624). Suitable amplification cycles are continued with primer 606 and primer 604 to provide an oligonucleotide amplicon suitable for sequencing on an Illumina sequencing platform. Additional rounds of amplification produce an oligonucleotide amplicon 608 comprising one or more constant regions 626, 624, an assay identifier 622, a sequence 620 of the 5' constant region 610 of the initial oligonucleotide 620, a sample identifier 612, a sequence of the 3' constant region 614, and an amplification region 628. Due to the constant region 626 and / or the amplification region 628, the oligonucleotide amplicon 608 is suitable for sequencing on a standard platform for large-scale parallel sequencing.

[0055] In some embodiments, the presence of a complementary DNA strand (as in the case of an adapter) may cause problems with detecting contamination or sequence variation if the complementary adapter strand contains both binding regions for the amplification primers. In this case, both strands will be amplified and any detected contamination / sequence variation may be due to sequence differences in the barcode sequences present on the two strands. In many cases, this will not occur with adapter designs.

[0056] Embodiment 1:

[0057] One embodiment of the method of the present invention is used to determine whether there is sample barcode contamination in a kit having Illumina adapter sequences. Figure 1AAs shown, an oligonucleotide 102 having a sample identifier 112 is flanked by an Illumina Index 1 sequence as its 5' constant region 110, and an Illumina P7' sequence as its 3' constant region 114. P7' represents the complementary sequence of P7; similarly, P5' represents the complementary sequence of P5. FIG. 1 shows a method for detecting contamination of this oligonucleotide 102 by an oligonucleotide having a different sample identifier. Amplification can be performed using a standard DNA polymerase, a P7 primer, and another primer comprising P5, a Read 1 primer sequence, a QC barcode, and an Index 1 sequence (from 5' to 3', respectively). A high-fidelity DNA polymerase can be used to reduce or minimize false contamination detection due to PCR errors.

[0058] The assay was developed using two versions or embodiments of the assay primers. The sequences of these two versions are shown in Figure 2 Initial attempts using version 1 of the assay primers (containing the reverse complement of the Illumina Read 1 primer and Illumina Read 2 (Index 1) primer sequences in the assay primers) produced a small amount of the expected 130 bp amplicon and a large amount of shorter amplification products ( Figure 3 These products are likely derived from secondary amplification products that arise from the 13 bp complementarity between the 3' end of Read 1 and the 5' end of Index 1. Most of these secondary amplification products were eliminated by changing the Read 1 sequence from the Illumina sequence to the QXT Read 1 sequence (version 2 of the assay primers). Figure 4 Lane B1 in Figure 5).

[0059] Embodiment 2:

[0060] The Haloplex and Haloplex HS kits were tested to see if oligonucleotides containing sample barcodes could be amplified in the Index solution provided in the kits. The oligonucleotides were found to amplify cleanly as a strong amplification product was generated when the assay primers were used ( Figure 4 , Lane B1 (Index solution provided)).

[0061] Embodiment 3:

[0062] The assay primers were tested with the SureSelect XT and SureSelect XT2 kits and the oligonucleotides were successfully amplified. The SureSelect XTHS kit was also tested with the assay primers of the invention, where the overlapping sequences were modified, and the oligonucleotides were successfully amplified.

[0063] Amplification of these libraries is possible even when the oligonucleotides are modified in a way that prevents elongation, since subsequent rounds after the first two use the synthesized molecules as templates. The amplification method can also be effective in the presence of a 5' biotin modification.

[0064] Embodiment 4:

[0065] A set of 96 or more sample identifiers is provided. This set can be used to add identifiers to nucleic acid samples before amplification and / or before pooling before sequencing. However, if one of these sample identifiers is contaminated during kit assembly or reagent preparation, it may result in the detection of low allele variants in the sample. To be sure that there is no contamination, many sequencing runs are required to ensure that each sample identifier can be confirmed to be free of contamination.

[0066] The following protocol overcomes this limitation and can be used to determine contamination of sample identifiers (also referred to in this embodiment as sample barcodes or SBCs) and / or assay identifiers (also referred to in this embodiment as QC barcodes or QCBCs). A set of 96 oligonucleotides containing different sample identifiers is divided into two groups: Group 1 and Group 2, each containing 48 oligonucleotides. Group 1 has SBC1 to SBC48 and Group 2 has SBC49 to SBC96. Each sample identifier in Group 1 is amplified with an assay primer containing one of the 48 different assay identifiers (QCBC1 to QCBC48). Each sample identifier in Group 2 is amplified using one of the same 48 assay identifiers used in Group 1, such that each assay identifier (QCBC1 to QCBC48) is present in both groups and both amplification reactions, and each sample identifier (SBC1 through SBC96) is present in only one group and one amplification reaction. Figure 7 The association of assay identifiers (QCBC) to sample identifiers (SBC) according to this protocol is shown in For purposes of illustration, the SBCs are shown arranged in a 96-well plate, although it is not necessary to provide or use them in a well plate.

[0067] PCR amplification produces oligonucleotide amplicons with QCBCs and SBCs. In the absence of contamination, each SBC is associated with one QCBC. In other words, when sequencing, the sequence information of each SBC should have a single QCBC associated with it. Figure 7The association that will be generated using this scheme is shown. However, it is desirable to sequence the amplicons in a pool, rather than using massively parallel sequencing alone, thereby reducing the time, expense, and workload required for sequencing. Therefore, the oligonucleotide amplicons generated in group 1 are pooled together and sequenced, and the oligonucleotide amplicons from group 2 are pooled together and sequenced. The sequencing of the pool generates sequence information for the different amplicons included in the pool, and the sequencing information for a given amplicon will have a sample identifier and an assay identifier associated therewith.

[0068] Based on the association identified after sequence information analysis, order-checking in this way will allow detection of contamination due to sample identifier or assay identifier. For this analysis, it is helpful to include all potential sample identifiers (whether they are expected to be present in the pool) in the sequencing information analysis. If contamination occurs, contamination may come from sample identifier or assay primer. The pattern that sample identifier and assay identifier occur in two sequencing pools (from group 1 and group 2) will determine whether sample identifier contamination or assay identifier contamination. This scheme allows people to determine which is the source of contamination.

[0069] If a sample identifier from Group 2 is observed in Group 1 (e.g., if the sequence of SBC66 is found in the sequencing information of Group 1), this indicates that one of the sample barcodes in Group 1 is contaminated because there are 49 sample identifiers instead of the expected 48. However, this knowledge alone does not indicate which sample identifiers in Group 1 are contaminated with SBC66. The specific sample barcode that is contaminated is determined based on which assay identifier is associated with the contaminating SBC66. If SBC66 found in the first pool is associated with QCBC10, then SBC10 is a sample identifier contaminated with SBC66. Any one of the sample identifiers in Group 1 has an assay identifier associated with it that is the same as the contaminating sample identifier (i.e., the contaminated sample identifier).

[0070] In addition, the methods, compositions and kits of the present invention can also detect contamination in a pool by identifying sample identifiers associated with more than one assay identifier and / or by identifying assay identifiers associated with more than one sample identifier. If the sequence information indicates that there are amplicons with SBC13 and QCBC13, and there are amplicons with SBC13 and QCBC29 (i.e., SBC13 is associated with QCBC13 and with QCBC29), it indicates that there is some contamination. However, this knowledge alone does not indicate whether SBC29 is contaminated by SBC13, or whether QCBC13 is contaminated by QCBC29. By identifying whether there is contamination with the same assay identifier in the second pool, the source of contamination can be identified. In the second pool, SBC61 will only be associated with QCBC13 if there is no contamination. However, if SBC61 is also associated with QCBC29, this indicates that QCBC13 is contaminated because contamination has occurred in both pools. If SBC61 is not associated with QCBC29, it means that QCBC13 is not contaminated and SBC29 is the source of contamination in the first pool. The same method is also valid for the group 1 sample identifiers present in the group 2 pool. The method of the present invention provides the ability to distinguish between sample identifier contamination and assay identifier contamination using two sequencing pools.

[0071] The methods and compositions of the present invention can also be used to determine sequence variation of random nucleotides found between two constant regions. The assay identifier can be used as a standard sample barcode, assuming that the sequencing output is sufficient to detect the expected contamination level, only one sample pool is required. For example, for sequences with a small variable region between two constant regions, the assay can be used to identify low levels of contamination occurring in the sequence, which may also be beneficial for identifying contamination or variation in oligonucleotides for any intended application.

[0072] The description of the foregoing exemplary or preferred embodiments should be considered to illustrate rather than limit the present invention as defined by the claims. Obviously, numerous variations and combinations of the features set forth above may be utilized without departing from the present invention as set forth in the claims. Such variations should not be considered to depart from the scope of the present invention, and all such variations are expected to be included within the scope of the following claims. All of these references cited herein are fully incorporated herein by reference. Sequence Listing <110> Agilent Technologies <120> Assay methods and compositions for detecting nucleic acid identifier contamination <130> 20170066-02 (027644-8322) <150> US 15 / 645,085 <151> 2017-07-10 <160> 8 <170> PatentIn version 3.5 <210> 1 <211> 20 <212> DNA <213> Artificial sequence <220> <223> synthetic sequence <400> 1 aatgatacgg cgaccaccga 20 <210> 2 <211> twenty four <212> DNA <213> Artificial sequence <220> <223> synthetic sequence <400> 2 caagcagaag acggcatacg agat 24 <210> 3 <211> 33 <212> DNA <213> Artificial sequence <220> <223> synthetic sequence <400> 3 acactctttc cctacacgac gctcttccga tct 33 <210> 4 <211> 33 <212> DNA <213> Artificial sequence <220> <223> synthetic sequence <400> 4 gatcggaaga gcacacgtct gaactccagt cac 33 <210> 5 <211> 34 <212> DNA <213> Artificial sequence <220> <223> synthetic sequence <400> 5 gtgactggag ttcagacgtg tgctcttccg atct 34 <210> 6 <211> 33 <212> DNA <213> Artificial sequence <220> <223> synthetic sequence <400> 6 agatcggaag agcgtcgtgt agggaaagag tgt 33 <210> 7 <211> 30 <212> DNA <213> Artificial sequence <220> <223> synthetic sequence <400> 7 ccatctcatc cctgcgtgtc tccgactcag 30 <210> 8 <211> twenty three <212> DNA <213> Artificial sequence <220> <223> synthetic sequence <400> 8 cctctctatg ggcagtcggt gat 23

Claims

1. A method for detecting contamination in a set of oligonucleotide samples, the method comprising: providing a set of oligonucleotide samples comprising oligonucleotides, wherein each oligonucleotide has a 5' constant region, a sample identifier and a 3' constant region, each oligonucleotide in one sample has the same sample identifier, and each sample in the group has a different sample identifier, Unless one or more samples are contaminated; amplifying the oligonucleotide or the complement of the oligonucleotide with an assay primer and a second primer, wherein the assay primers are different for each sample, wherein each assay primer comprises a priming portion complementary to at least a portion of a 5' constant region of the oligonucleotide, or a complement thereof, and an assay identifier, and the second primer comprises a priming portion complementary to at least a portion of a 3' constant region of the oligonucleotide, or a complement thereof, thereby generating a set of oligonucleotide amplicons, wherein each oligonucleotide amplicon comprises one of the assay identifiers, the 5' constant region, one of the sample identifiers, and the 3' constant region; pooling the oligonucleotide amplicons in one or more pools; sequencing the one or more pools to determine the sequence of at least the sample identifier and the assay identifier of the oligonucleotide amplicons; and A determination is made as to whether sample identifiers in one or more pools include contaminating sample identifiers.

2. The method of claim 1, further comprising determining whether the assay identifiers in the first pool include contaminating assay identifiers.

3. The method of claim 1 or 2, wherein the contaminating sample identifier is determined by one or both of: (i) identifying at least one sample identifier associated with more than one assay identifier, and (ii) identifying at least one assay identifier associated with more than one sample identifier.

4. The method of any one of claims 1-3, wherein the one or more pools comprise a first pool and a second pool; sequencing the first and second pools, respectively, to determine the sequence of at least the sample identifier and the assay identifier of the oligonucleotide amplicons; A determination is made as to whether the sample identifiers in the second pool include contaminating sample identifiers.

5. The method of claim 4, further comprising determining whether the assay identifiers in the second pool include contaminating assay identifiers.

6. The method of claim 4, wherein the method further comprises: The contaminating sample identifier is identified by determining that the contaminating sample identifier is from the second pool.

7. The method of claim 4, wherein the method further comprises: The contaminating sample identifier is identified by determining that the second pool does not include the contaminating assay identifier.

8. The method of claim 4, wherein the method further comprises: The contaminating assay identifier is identified by determining that the second pool includes the contaminating assay identifier.

9. The method of any one of claims 1 to 7, wherein the set of oligonucleotides comprises at least 8 oligonucleotides.

10. The method of any one of claims 1 to 8, further comprising one or both of the following: grouping the sequences of the oligonucleotide amplicons according to the assay identifier to form assay groups, and determining whether more than one sample identifier sequence is present in each assay group; and The sequences of the oligonucleotide amplicons are grouped according to the sample identifier to form sample groups, and it is determined whether more than one assay identifier sequence is present in each sample group.

11. The method of claim 1, comprising determining a mismatch between at least one assay identifier and at least one sample identifier.